Imagine a smart alarm for the brain that doesn't just warn you, but acts. It monitors hormone levels to spot a deadly seizure before it happens. Once detected, it automatically delivers a life-saving drug to stop the event in its tracks.
There is currently no way to predict or prevent Sudden Unexpected Death in Epilepsy (SUDEP), leaving millions of patients and families in constant fear.
A prototype for a SUDEP Medical Device (SMD) that uses AI and biosensors to detect life-threatening seizures and automatically administer drugs.
If you are a manufacturer dealing with the lack of preventative tools for SUDEP — this project developed a prototype medical device that uses AI to trigger emergency drug administration. This allows for a new product line targeting the 65 million people with epilepsy.
If you are a software firm dealing with the difficulty of predicting life-threatening seizures — this project developed AI models based on neuroendocrine processes. This provides a validated logic for building predictive mortality alerts.
If you are a pharma company dealing with the need for precise, automated drug timing — this project developed a system that triggers drug administration based on biosensor data. This creates a high-value delivery mechanism for emergency epilepsy medications.
Based on available project data, there is no information regarding the production cost or market price of the device.
The project is currently focused on developing a prototype. Based on available project data, industrial scaling plans are not yet detailed.
The consortium includes Biostrike, which specifically handles IP and marketing, suggesting a structured approach to intellectual property, though specific licenses are not listed.
The consortium includes Kinetikos Health to provide specific expertise in GDPR and HIPAA knowledge for medical device implementation.
The project runs from 2022-06-01 to 2026-11-30, indicating that the prototype development phase continues until late 2026.
The consortium is highly diversified with 9 partners across 5 countries. It maintains a strong commercial orientation with a 33% industry ratio (3 industrial partners, including 2 SMEs). The mix of academic research (3 universities, 3 research centers) and specialized business entities for IP, marketing, and GDPR compliance indicates a clear path from lab to market.
Contact I3S - Instituto de Investigacao e Inovacao em Saude da Universidade do Porto
Contact us to explore licensing opportunities for the SMD prototype.
